Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMO8IEZ)

• Drug Name: LY-2828360 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Pain	MG30-MG3Z	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 46833780
  TTD Drug ID: DMO8IEZ

Molecule-Related Drug Atlas

Drug(s) Targeting Cannabinoid receptor 2 (CB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Guanfacine extended release	DMB1CZ8	Attention deficit hyperactivity disorder	6A05.Z	Approved	[3]
NABILONE	DMVRYT2	Insomnia	7A00-7A0Z	Approved	[4]
GW-42004	DMY3KSU	Lipid metabolism disorder	5C52.Z	Phase 2	[5]
KHK-6188	DMF6CTI	Neuropathic pain	8E43.0	Phase 2	[2]
APD371	DM3XT5V	Crohn disease	DD70	Phase 2	[6]
S-777469	DMZGNOJ	Atopic dermatitis	EA80	Phase 2	[7]
842166X	DMOV0AP	Pain	MG30-MG3Z	Phase 2	[8]
Beta-caryophyllene	DM7583A	Pain	MG30-MG3Z	Phase 2	[9]
Vicasinabin	DMF16CU	Diabetic retinopathy	9B71.0	Phase 2	[10]
Tedalinab	DM58J7E	Pain	MG30-MG3Z	Phase 1	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cannabinoid receptor 2 (CB2)	TTMSFAW	CNR2_HUMAN	Agonist	[2]

References

• [1] ClinicalTrials.gov (NCT01319929) A Study of LY2828360 in Patients With Osteoarthritic Knee Pain. U.S. National Institutes of Health.
• [2] Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2).
• [3] Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81.
• [4] Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
• [5] Company report (Gwpharm)
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2009 Mar;14(1):165-79.
• [8] The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies. Yao Xue Xue Bao. 2013 Sep;48(9):1436-49.
• [9] The cannabinoid CB1 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol. 2014 Apr;24(4):608-20.
• [10] Clinical pipeline report, company report or official report of Roche
• [11] Cannabinoid CB2 receptor (CNR2). SciBX 3(46); doi:10.1038/scibx.2010.1384. Dec. 2 2010